Home Featured Page 8

Featured

Latest

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

JOURNEYS: A Film Experience + Live Conversation with the Filmmakers

Psychedelic Policy Briefing: Week of July 20th, 2026

The Psychedelic Practitioner Issue 4: Integration

Shane Mauss – Comedy and Molecules – Episode 14

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of...

The Psychedelic Writers Guild’s Denver Mixer

The Mushroom Cure – Special Live Filming

Pα+ Psychedelic Bulletin #222: Unpacking EPIsoDE; Meta-Analysis Says Psychedelics No Better...

BREAKING: Otsuka to Acquire Methylone Drug Developer Transcend in $1.23B Deal

EDITOR PICKS

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on...

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

JOURNEYS: A Film Experience + Live Conversation with the Filmmakers

Psychedelic Policy Briefing: Week of July 20th, 2026

The Psychedelic Practitioner Issue 4: Integration

Shane Mauss – Comedy and Molecules – Episode 14

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

Quarterly Briefing: Q1 2026

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of...

The Psychedelic Writers Guild’s Denver Mixer

The Mushroom Cure – Special Live Filming

Pα+ Psychedelic Bulletin #222: Unpacking EPIsoDE; Meta-Analysis Says Psychedelics No Better...

BREAKING: Otsuka to Acquire Methylone Drug Developer Transcend in $1.23B Deal

EDITOR PICKS

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on...

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY